This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To determine whether neutralizing antibodies (NABs) to interferon beta (IFNβ)-1a (Avonex) and IFNβ-1b (Betaseron) cross-react.
Background: A total of 38% of MS patients treated with IFNβ-1b and 22% of those treated with IFNβ-1a were reported to develop NABs, which could reduce the clinical efficacy of the drug.
Methods: Blood from 10 MS patients was collected before and at 3 and 6 months after initiating treatment with IFNβ-1a. ELISA was performed to detect binding antibodies to IFNβ-1a. Sera from patients who tested positive for binding antibodies to IFNβ-1a were then screened for NABs to IFNβ-1a in a biologic assay based on neutralization of antiviral activity. These serum samples were subsequently tested for cross-reactivity with IFNβ-1b both in the ELISA and the biologic assay. In the second part of the study, sera from patients who participated in the phase III IFNβ-1b trial at the University of Maryland were examined for cross-reactivity with IFNβ-1a in the ELISA and the biologic assay.
Results: Of the 10 patients treated with IFNβ-1a, three developed binding as well as NABs to IFNβ-1a 6 months after treatment, and these antibodies cross-reacted with IFNβ-1b both in the binding and the biologic assay. Similarly, sera from six patients with NABs to IFNβ-1b showed cross-reactivity with IFNβ-1a in the binding assay. Three of these six serum samples tested for neutralizing activity against IFNβ-1a demonstrated the presence of NABs to IFNβ-1a.
Conclusions: NABs to IFNβ-1a (Avonex) and IFNβ-1b (Betaseron) cross-react, both in the binding and the biologic assays. This suggests that switching to alternate IFNβ preparation in patients who develop NABs may not be clinically beneficial. Studies examining cross-reactivity between NABs to IFNβ-1a and IFNβ-1b in a large number of patients are indicated.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Alert Me
Recommended articles
Effect of neutralizing antibodies on biomarker responses to interferon beta
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
Neutralizing antibodies and efficacy of interferon β-1a
Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients